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Background. Dengue fever is the most common arboviral disease in travelers. In countries where dengue virus
is endemic, sequential (secondary) infections with different dengue virus serotypes are associated with disease
severity. Data on severity and secondary infection rates in a population of travelers are lacking.
Methods. Intensified surveillance of dengue fever in travelers was performed within the European Network
on Surveillance of Imported Infectious Diseases. Data were collected at 14 European clinical referral centers between
2003 and 2005.
Results. A total of 219 dengue virus infections imported from various regions of endemicity were reported.
Serological analysis revealed a secondary immune response in 17%. Spontaneous bleeding was observed in 17
(8%) patients and was associated with increased serum alanine and aspartate aminotransferase levels and lower
median platelet counts. Two (0.9%) patients fulfilled the World Health Organization (WHO) case definition for
dengue hemorrhagic fever. However, 23 (11%) travelers had severe clinical manifestations (internal hemorrhage,
plasma leakage, shock, or marked thrombocytopenia). A secondary immune response was significantly associated
with both spontaneous bleeding and other severe clinical manifestations.
Conclusions. In travelers, severe dengue virus infections are not uncommon but may be missed if the WHO
classification is strictly applied. High liver enzyme levels and low platelet counts could serve as indicators of disease
severity.
Dengue fever is increasingly recognized to be the most
important arboviral infection in travelers [1]. Among
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17,353 ill travelers reported in the surveillance network
GeoSentinel, dengue virus infection was, in travelers
with specific diagnoses, the leading cause of febrile ill-
ness for every geographic region except sub-Saharan
Africa and Central America [2]. With a 30-fold growth
in incidence over the past 50 years worldwide, the dis-
ease has expanded its geographical distribution to al-
most all tropical and subtropical countries [3, 4]. Re-
cently, the virus has spread to the Middle East [5] and
the US states of Hawaii and Texas [6, 7]. At the same
time, the activity of international air travel is contin-
uously increasing. According to the World Tourism Or-
ganization, the number of international tourist arrivals
recorded worldwide in 2005 was 1800 million persons
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for the first time ever [8]. Therefore, health care providers in
industrialized countries should have an understanding of the
clinical spectrum of the disease and its diagnosis when man-
aging returning travelers.
As in populations living in areas of endemicity, most dengue
virus infections in travelers are asymptomatic [9]. The mani-
festations of symptomatic disease range, however, from mild
febrile illness to a severe form with clinical bleeding and shock
caused by plasma leakage (dengue hemorrhagic fever [DHF]).
The exact mechanism of enhanced severity is not fully under-
stood, but secondary dengue virus infection, defined as se-
quential infection with 2 of the 4 heterologous serotypes (DEN-
1, -2, -3, and -4), is thought to be the main factor [10, 11].
Differences in viral virulence and host characteristics (genetic
dispositions or underlying diseases) seem to play an important
role as well [12, 13].
Infection with one dengue virus serotype confers lifelong
immunity to that specific serotype but leads only to a few
months of cross-immunity that protects from disease caused
by 1 of the other 3 dengue virus serotypes [4]. This temporary
cross-immunity might explain to some extent why DHF is
rarely seen in travelers. Nonetheless, fatal dengue associated
with fulminant hepatic failure [14] or subarachnoidal hem-
orrhage [15] have recently been reported in travelers. Severe
manifestations of dengue virus infection, such as encephalitis
[16] or visual loss [17], have also been reported in returning
travelers in recent years. Severe postdengue depression has been
described in a Spanish traveler that resulted in suicide [18].
In travelers, our knowledge about severe dengue manifes-
tations is mainly based on published single case reports. Reliable
data on disease severity and on clinical and laboratory features
of dengue virus infection are uncommon [1, 19–22]. In par-
ticular, the impact on morbidity and mortality of secondary
dengue virus infections in travelers has not been correctly
estimated.
PATIENTS, MATERIALS, AND METHODS
The present study was established within the infrastructure of
the European Network on Surveillance of Imported Infectious
Diseases (TropNetEurop) [22]. Sentinel surveillance reporting
is currently performed by 51 participating clinical sites through-
out 17 European countries using a standardized and comput-
erized reporting system. All member sites are large referral cen-
ters for tropical or travel medicine, where ∼63,000 patients
annually present spontaneously or are referred with symptoms
after travel.
Since May 2003, surveillance has been intensified by use of
an additional standardized questionnaire covering dengue-spe-
cific issues: dengue-related symptoms, serological results, he-
matological values, chemical constituents of the blood, history
of previous travel, and immunizations. Anonymous data col-
lected from patients with dengue virus infection who presented
spontaneously or by referral between May 2003 and December
2005 at 1 of 14 participating clinical sites of the network were
sent to the coordination center in Berlin.
According to the World Health Organization (WHO) [23],
reported patients were classified into 2 categories: patients with
probable and those with confirmed dengue virus infection. For
confirmation, the virus was detected by reverse-transcriptase
polymerase chain reaction (RT-PCR) or by a significant change
in IgM or IgG antibody titers in paired serum samples. A prob-
able diagnosis of dengue virus infection was supported by a
single positive IgM antibody test on a late acute- or convales-
cent-phase serum specimen (i.e., 4–7 or 8–45 days, respectively,
after the onset of symptoms). The serological analysis was per-
formed at the clinical sites, which are all specialized centers. In
cases where an ELISA kit was used and both IgM and IgG
quantitative test results were available, the evaluation of pa-
tients’ immune response was performed in accordance with the
manufacturer’s instructions. For the most commonly used
combination of PanBio IgM capture ELISA and IgG indirect
ELISA (PanBio), a secondary immune response was defined as
having a sample:calibrator absorbance ratio for IgG of 4 in
the presence of an IgM ratio of1. For RT-PCR analysis, either
center-specific in-house test kits were used or (most often)
samples were sent to a reference center where RT-PCR was
performed as described elsewhere [24].
The WHO clinical case definition for DHF was applied and
required the presence of all 4 criteria: fever, platelet count
!100,000 cells/mm3, hemorrhagic tendency, and evidence of
capillary leakage (i.e., hematocrit increase of 20% from base-
line, pleural effusion, ascites, or hypoproteinemia) [23]. Hem-
orrhagic tendency was defined as spontaneous bleeding or signs
of capillary fragility [23]. Spontaneous bleeding was evidenced
as bleeding from the nose, gums, or gastrointestinal (GI) tract
or hypermenorrhea or ecchymosis. Petechiae and a positive
tourniquet test were considered to be signs of capillary fragility.
As used in previous publications [25, 26], severe clinical
manifestations were defined as internal hemorrhage, plasma
leakage, shock (i.e., hypotension for age or pulse pressure20
mm Hg), and/or a platelet count 50,000 cells/mm3. Internal
hemorrhage consisted of GI-tract bleeding and/or hypermen-
orrhea. Leukopenia was defined as a white blood cell (WBC)
count 4500 cells/mm3 and thrombocytopenia as a platelet
count 150,000 cells/mm3. The increase in aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) levels
was graded in accordance with the normal values of each mem-
ber site’s laboratory. For the analysis of laboratory features,
only patients who presented during the acute phase (i.e., 10
days after the onset of symptoms) of illness were included.
All data were entered into a Microsoft Access database (Mi-
crosoft Access 2002; Microsoft) and exported to SPSS software
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Table 1. Geographic regions in which
219 travelers acquired a dengue virus
infection (2003–2005).
Region, country
Subjects with
dengue, no. (%)
Asia
Southeast Asia 77 (35.2)
Indian subcontinent 63 (28.8)
Rest of Asia 1 (0.5)
The Americas
Central America 39 (17.8)
South America 16 (7.3)
Caribbean 7 (3.2)
Africa
Central Africa 2 (0.9)
East Africa 10 (4.6)
West Africa 2 (0.9)
South Africa 2 (0.9)
Total 219 (100)
(version 13.0 for Windows; SPSS). Groups with and without
specific presentations were compared by x2 tests. A statistically
significant difference was determined by . For multi-P ! .05
variate analysis, logistic regression models were applied using
stepwise backward removal with the inclusion of age, sex, and
all variables that had in univariate analysis in the firstP .1
step. Crude odds ratios and their Cornfield 95% confidence
intervals were calculated.
RESULTS
Patients’ characteristics and travel history. During the study
period, a total of 219 patients (109 male and 110 female) with
acute or recent dengue virus infections were reported (median
age, 32 years; range, 11–70 years). Most patients (90%) were
European, and 17 (8%) were of non-European origin but were
living in ( ) or visiting ( ) Europe (information wasnp 15 np 2
missing for 6 patients). All patients of non-European origin
were born in countries where dengue is endemic. Nearly all
patients acquired the dengue virus infection either in Southeast
Asia ( [35%]), the Indian subcontinent ( [29%]),np 77 np 63
or the Americas ( [28%]) (table 1). Among patientsnp 62
who visited 1 country only, India ( [23%]), Thailandnp 43
( [17%]), and Sri Lanka ( [8%]) topped the listnp 31 np 15
of 39 countries. The median duration of travel was 24 days
(range, 4 days–4 years). For 39%, it was their first visit to a
country where dengue is endemic, whereas 61% had made
previous visits (1–3 times, 37%; 13 times, 24%). Six patients
(2.7%) had a history of documented dengue virus infection in
the past.
Diagnosis of dengue virus infection and patients’ immune
response. Dengue virus infection was confirmed in 133 pa-
tients (61%) and was diagnosed as probable in the remaining
86 (39%). Confirmation was achieved in 115 cases by increasing
dengue antibody titers in paired serum samples, in 2 by PCR
only, and in 16 by combining both methods. A probable di-
agnosis was established in 86 patients with at least a positive
IgM antibody titer in a single serum sample (57 had a positive
IgG result as well). For serological analysis, most often (np
[79%]) the commercially available PanBio-ELISA was used174
to detect both IgM and IgG antibodies. There was no significant
difference in the frequency of clinical, laboratory, or demo-
graphic characteristics between the population with probable
and confirmed dengue virus infection.
Serological analysis indicated a primary immune response in
134 patients (77%) and a secondary immune response in 40
patients (23%). In 45 cases (37 probable and 8 confirmed in-
fections), the discrimination was not possible because of miss-
ing quantitative IgM or IgG levels. Thirteen patients with a
secondary immune response were excluded from the analysis
because of a history of flavivirus immunization (11 against
yellow fever, 2 against tickborne encephalitis, and 0 against
Japanese encephalitis). Thus, 27 patients (17%) were regarded
as having acquired a secondary dengue virus infection. Euro-
peans were significantly less likely to exhibit a secondary im-
mune response than were persons of non-European origin
(14% vs. 50%; ).Pp .001
Clinical and hematological features. Clinical manifesta-
tions associated with dengue virus infection are presented in
table 2. Petechiae occurred in 28 patients (13%) and sponta-
neous bleeding in 17 patients (8%). Spontaneous bleeding pre-
sented most often as bleeding from the nose or gum. One
patient developed GI-tract bleeding presenting as hematemesis.
At 4 study sites, a tourniquet test was applied in a total of
82 patients, with 36 (44%) showing a positive test result. A
positive test was associated with the occurrence of petechiae
(42% vs. 2%; ) but not with spontaneous bleeding (24%P ! .001
vs. 8%; ). Furthermore, there was no significant asso-Pp .1
ciation between a positive test and the frequency of severe
clinical manifestation (21% vs. 5%; ), a platelet countPp .07
!100,000 cells/mm3 ( ), being of non-European originPp .59
( ), secondary immune response ( ), or a 13-foldPp .4 Pp .3
increased AST level ( ). A 13-fold increased ALT levelPp .3
was associated with a positive test result ( ). There wasPp .02
no difference in the median duration of symptoms before the
test was applied (positive/negative result, 5 vs. 4 days; ).Pp .9
As shown in table 3, most patients had either a low WBC
or platelet count during the acute phase of illness. Eighteen
patients (10%) had marked thrombocytopenia with a platelet
count !50,000 cells/mm3, and 2 patients (1%) had counts
!20,000 cells/mm3. Among those patients tested, more than
half had increased liver enzyme levels. Table 3 shows the most
abnormal values observed in each patient over the course of
the disease, demonstrating that most abnormal WBC or platelet
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Table 2. Clinical presentations of dengue in 219
travelers (multiple entries possible).
Symptom
Subjects
presenting, no. (%)
Fever 203 (92.7)
Headache 152 (69.4)
Fatigue 124 (56.6)
Rash 116 (53.0)
Muscle pain 109 (49.8)
Retroorbital pain 96 (43.8)
Hemorrhagic tendenciesa 57 (26.0)
Tourniquet testb 36 (43.9)
Petechiae 28 (12.8)
Spontaneous bleeding 17 (7.8)
Epistaxis 6 (2.7)
Gum bleeding 5 (2.3)
Hypermenorrheac 3 (2.7)
Ecchymosis 4 (1.8)
GI-tract bleeding 1 (0.5)
Diarrhea 54 (24.7)
Pruritus 46 (21.0)
Change in taste 32 (14.6)
Vomiting 29 (13.2)
Splenomegaly 9 (4.1)
Lymphadenopathy 8 (3.7)
Neuropsychological symptoms 7 (3.2)
Hypotension for age 1 (0.5)
NOTE. GI, gastrointestinal.
a Defined as spontaneous bleeding and/or signs of capillary
fragility (i.e., positive tourniquet test and petechiae).
b Total of 82 subjects tested.
c A total of 110 subjects were female.
values were found between 3 and 6 days after the onset of
symptoms, whereas most abnormal AST, ALT, or lactate de-
hydrogenase values were often found later. Table 4 shows lab-
oratory features in patient groups with different clinical pre-
sentations and trends of platelet counts, liver enzyme levels,
and frequencies of secondary dengue virus infections.
Only 2 (0.9%) patients fulfilled the WHO clinical case def-
inition for DHF—both had evidence of hemoconcentration,
with hematocrit increasing by 20% over the course of the
disease, in addition to fever, hemorrhagic tendencies, and a
platelet count !100,000 cells/mm3. Serological analysis was
compatible with a primary infection in 1 patient and with a
secondary infection in the other. Neither developed signs of
shock.
Associations with spontaneous bleeding. A total of 17 pa-
tients (8%) had spontaneous bleeding that was associated with
secondary immune response, with non-European origin and
with a 13-fold increased serum ALT level in multivariate anal-
ysis (table 5). The median platelet count in patients with spon-
taneous bleeding was 72,000 cells/mm3 (range, 17,000–349,000
cells/mm3); that in patients without spontaneous bleeding was
110,000 cells/mm3 ( ).Pp .06
Associations with severe clinical manifestations. A total of
23 patients (11%) demonstrated manifestations of severe den-
gue disease (internal hemorrhage, 4; plasma leakage, 2; shock,
1; and platelet count 50,000 cells/mm3, 18). In multivariate
analysis, secondary immune response and a 13-fold increased
serum AST level were the only independent predictors of severe
manifestations (table 5). There was no association between se-
vere dengue disease and the median duration of travel abroad
(21 vs. 25 days; ). Eight patients (34%) with severe clin-Pp .5
ical manifestations and 5 (29%) with spontaneous bleeding had
visited a dengue-endemic country the first time.
Other complications and hospitalization rate. A total of
51 patients (23%) required hospitalization because of compli-
cations or aggravation of dengue-related symptoms. The me-
dium duration of hospitalization was 4 days (range, 1–11 days).
A 60-year-old patient with spontaneous bleeding required treat-
ment at an intensive care unit because of atrial fibrillations
during the acute phase of illness (first time with no history of
underlining cardiac disease; after recovery, there were normal
findings in stress echocardiography and scintigraphy). One pa-
tient complained of blurred vision with black dots in the vision
field of both eyes (which disappeared gradually over the course
of 2 months without sequelae), and 1 patient presented with
hypotension for age.
DISCUSSION
In many European countries, notification of imported den-
gue virus infections is not mandatory. Therefore, only few
publications are available describing large populations of trav-
elers with dengue virus infection [19–22, 27, 28]. Most of these
focused on epidemiological or basic clinical data only. Here,
we present more complete clinical and hematological data col-
lected from 1200 dengue virus–infected travelers, as well as
estimates on the rate of secondary (sequential) infections and
the usefulness of the tourniquet test in a population of travelers.
The diagnostic value of the tourniquet test was recently eval-
uated in a large study among 905 Vietnamese children; positive
results were found in only 42% of dengue virus–infected pa-
tients [29]. The test was regarded to be a cheap and simple
clinical method that is suggestive of dengue when positive, but
a negative test does not exclude the disease. In our population
of international travelers, the sensitivity of the test was relatively
low at 44%, as in the Vietnamese study. The sensitivity of the
test can be improved by repeated testing, but this was not
performed in many cases, because most patients presented to
outpatient departments. In our population, a positive test was
not associated with lower platelet counts or spontaneous bleed-
ing. This has also been seen in Thai patients with dengue [30]
and is a direct consequence of the fact that the tourniquet test
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Table 3. Laboratory features in 176 travelers with dengue fever presenting during the
acute phase of illness (10 days after the onset of symptoms).
Laboratory feature All
Days after onset of
symptoms
0–2 3–6 7–10
Leukopenia (!4500 cells/mm3) 130 (74) 16 (69) 96 (85) 18 (60)
Thrombocytopenia (!150,000 cells/mm3) 123 (71) 10 (53) 80 (76) 33 (70)
Leuko- and thrombocytopenia 104 (60) 12 (52) 76 (67) 16 (53)
Marked thrombocytopenia (!50,000 cells/mm3) 18 (10) 1 (5) 11 (11) 6 (13)
AST (n p 149)
Mild increase (!3-fold) 58 (34) 6 (40) 27 (43) 22 (33)
Moderate increase (3–5-fold) 25 (17) 0 12 (19) 12 (18)
Severe increase (15-fold) 18 (12) 0 5 (8) 13 (19)
ALT (n p 165)
Mild increase (!3-fold) 59 (36) 2 (12) 20 (35) 18 (30)
Moderate increase (3–5-fold) 18 (11) 0 8 (14) 6 (10)
Severe increase (15-fold) 21 (13) 0 2 (3) 14 (23)
LDH increase (n p 104) 70 (67) 6 (50) 31 (65) 21 (72)
NOTE. Data are no. (%) of subjects. The most abnormal values observed over the course of illness
are presented stratified by time after onset of symptoms. In several cases, the most abnormal value
for serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), and lactate dehy-
drogenase (LDH) were observed 110 days after the onset of symptoms.
measures capillary fragility rather than a tendency toward sys-
temic bleeding. By contrast, a positive test result was associated
with the presence of petechiae, which can also be regarded as
a sign of capillary fragility. Most important, the test cannot be
used to predict spontaneous bleeding or to distinguish between
severe and nonsevere disease.
ELISAs [31] can be used to classify dengue virus infection
as primary or secondary by determining the ratio of units of
dengue IgM:IgG antibody titers. High IgG levels are indicative
of secondary infections. Vaughn et al. [32] demonstrated, with
a panel of 78 dengue samples, that the PanBio-ELISA was able
to classify 100% of the primary and 96% of the secondary
infections correctly when a cutoff value of 3.0 was applied.
However, previous immunization against other flaviviruses may
render the IgG ELISA test less specific because of cross-reaction
[33]. Therefore, we chose a cutoff value of 4.0, as recommended
by the manufacturer, and we excluded patients with previous
immunizations against other flaviviruses from the analysis of
the immune response. Even then, 27 travelers (17%) demon-
strated an antibody immune response indicative of secondary
dengue virus infection. Furthermore, previously acquired fla-
vivirus infections other than dengue could have resulted in a
positive IgG response. The very low incidence of yellow fever
and Japanese encephalitis in travelers, however, suggests that
cross-reactivity with antibodies from other flavivirus infections
was negligible in the present study. In our population, the
relatively high proportion of travelers with secondary dengue
virus infections is a reflection of the fact that 61% had traveled
to a dengue-endemic country before. It can be suggested that,
of the millions of people traveling every year to areas where
dengue is endemic [8], a considerable proportion will have
visited these areas more than once, too.
Of 77 patients diagnosed with dengue in the United States
between 2001 and 2004, 8 (10%) had a primary infection and
12 (16%) had a secondary infection (for the remaining 57
patients, the distinction was not able to be determined) [21].
In this population, the majority of travelers reported recent
travel to a Caribbean island (30%), to a Pacific island (21%),
or to Asia (17%). These figures reflect travel habits, as they do
in our study population, that consisted mainly of Europeans
traveling for tourism to Southeast Asia, the Indian subconti-
nent, and the Americas. From all of the hitherto published
series, the data collected within TropNetEurop are probably the
most representative for European travelers, given that 14 major
referral centers from 8 different countries of the continent par-
ticipated in the surveillance.
In the present study, a few unusual clinical observations as-
sociated with dengue virus infection were made. One patient
presented with dengue disease complicated by blurred vision,
and another patient had acute atrial fibrillation. Ophthalmic
complications have been described in the literature [34],
whereas cardiac complications are rare and manifest usually as
myocarditis [35]. Our patient did not have signs of myocarditis
in laboratory or echocardiological examinations. Obviously, it
cannot be proved whether atrial fibrillation was directly caused
by the dengue virus infection or was instead triggered by a
febrile stress. There is only one other published case of a patient
with dengue disease developing acute atrial fibrillation [36].
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Table 4. Laboratory features in 176 travelers with dengue fever presenting during the acute phase of illness (10 days
after the onset of symptoms), classified by bleeding category and the presence of severe clinical manifestations (the
most abnormal value in each patient is shown).
Laboratory feature
Bleeding category Clinical severity category
No hemorrhagic
tendency
(n p 121)
Petechiae or
positive TT only
(n p 38)
Spontaneous
bleeding
(n p 17)
No severe
manifestations
(n p 154)
Severea
manifestations
(n p 22)
HCT, mean  SD, % 42.5  5.5 43.2  4.5 42.8  3.3 42.6  5.3 43.2  4.1
WBC count, cells/mm3 3.2 (1.1–10.6) 2.6b (1.0–6.7) 3.2 (1.5–5.6) 3.1 (1.0–10.6) 2.4c (1.4–5.6)
Platelet count, cells/mm3 120 (25–369) 93 (18–228) 72b (17–349) 121 (17–349) 40c (17–349)
ALT, U/L 56 (10–695) 70 (6–502) 159b (11–448) 56 (6–595) 87c (35–695)
AST, U/L 56 (10–695) 72 (12–564) 115b (14–442) 55 (12–695) 129c (30–588)
Secondary immune response, % 11 21 46b 13 44c
NOTE. Data are median (range) values, unless otherwise indicated. ALT, serum alanine aminotransferase; AST, serum aspartate aminotrans-
ferase, HCT, hematocrit; TT, tourniquet test; WBC, white blood cell.
a Defined as the presence of internal hemorrhage, signs of plasma leakage, shock, and/or a platelet count 50,000 cells/mm3.
b Significant difference vs. patients without hemorrhagic tendency ( ).P ! .05
c Significant difference vs. patients without severe manifestations ( ).P ! .05
Table 5. Laboratory values and other factors associated with spontaneous bleeding and other severe clinical man-
ifestations in 176 travelers with dengue virus infections.
Factor
Spontaneous bleedinga (n p 17) Severe clinical manifestationsb (n p 22)
Univariate analysis,
OR (95% CI)
Multivariate analysis,
OR (95% CI)
Univariate analysis,
OR (95% CI)
Multivariate analysis,
OR (95% CI)
Low platelet count
(!100,000 cells/mm3) 3.1 (0.95–10.7) NS … …
AST increase (13-fold) 3.5 (1.1–11.4) NS 3.5 (1.2–10.0) 3.7 (1.1–12.6)
ALT increase (13-fold) 3.3 (1.1–10.4) 5.4 (1.3–21.3) 1.7 (0.6–5.1) NS
Non-European origin 3.7 (0.9–15.2) 6.4 (1.3–32.3) 3.8 (1.0–13.9) NS
Secondary immune response 5.3 (1.4–20.8) 3.9 (1.04–14.5) 5.1 (1.4–17.7) 5.6 (1.7–19.2)
Increased LDH 4.9 (0.6–107.0) NS Undefined NS
NOTE. In multivariate analysis, odds ratios (ORs) are adjusted for age and sex. Bold type indicates significant results. ALT, serum alanine
aminotransferase; AST, serum aspartate aminotransferase; CI, confidence interval; LDH, lactate dehydrogenase; NS, not significant.
a Defined as bleeding from nose/gums, ecchymosis, or internal hemorrhage (bleeding from the gastrointestinal tract or hypermenorrhea).
b Defined as the presence of internal hemorrhage, signs of plasma leakage, shock, and/or platelet count 50,000 cells/mm3. Because a
very low platelet count was used in the definition, the variable was not included in the logistic regression model.
Underlying chronic diseases, which are likely to be more prev-
alent in a population of adult travelers than in the children
usually affected in countries where dengue is endemic, may
cause or mimic “unusual” dengue manifestations.
In areas of endemicity, ∼6% of symptomatic dengue virus
infections lead to DHF [37]. In our population, only 0.9% of
travelers with symptomatic disease fulfilled the WHO case def-
inition for DHF, probably because of the comparatively lower
prevalence of preexisting dengue antibodies among Europeans.
Nonetheless, in recent years, the validity of the WHO classi-
fication scheme to define severe dengue disease, which is based
on studies of children in Southeast Asia in the 1960s, has been
put in doubt [25, 38–41]. Balmaseda et al. [25] found that,
especially in adults, the WHO classification is difficult to apply,
with many severe cases being missed: more than two-thirds of
all adults with severe dengue manifestations were not classified
as having DHF. Although shock and plasma leakage seem to
be more prevalent as age decreases, the frequency of internal
hemorrhage augments as age increases [26]. On the basis of
these findings, some authors have raised the question whether
DHF represents an entirely separate physiopathological mech-
anism or whether it reflects only the extreme end of a gradual
systemic deterioration triggered by dengue [38]. The relatively
low proportion of patients (8%) with spontaneous bleeding
(including 4 with internal hemorrhage and only 3 with plasma
leakage or shock) and the high proportion of marked throm-
bocytopenia and of capillary fragility observed in the present
study support the latter view. In addition, the more arbitrary
platelet threshold of 100,000 cells/mm3, which is integrated into
the WHO case definition, failed to predict spontaneous bleed-
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ing in our population. However, patients with spontaneous
bleeding or other severe clinical manifestation had significantly
lower median platelet counts.
The definition of severe dengue disease is not uniform among
published studies. In a study of adults in Nicaragua [25, 26],
severe disease was defined by the presence of at least 1 of 4
clinical signs. In our series, 11% of patients had at least 1 of
those features. However, it must be taken into account that our
patients were recruited at outpatient departments and clinics
of specialized institutions only. Therefore, travelers with asymp-
tomatic infections or mild disease are often missed, which leads
to an artificially high rate of severe manifestations.
Median serum levels of both AST and ALT were higher in
patients with spontaneous bleeding and other severe manifes-
tations. In multivariate analysis, AST levels increased by 13-
fold were independently associated with severe manifestations,
and ALT levels increased by 13-fold with spontaneous bleeding.
Previous publications have suggested that increased liver en-
zymes could be used as an indicator for disease severity [40].
The first published fatal case of travel-acquired dengue infection
was complicated by fulminant hepatic failure [14]. It has to be
pointed out, however, that there was a great range in the lab-
oratory values, which limits their predictive value as markers
for bleeding or severe disease in single patients. In addition,
the time of blood collection must be taken into account: Al-
though most abnormal platelet and WBC values were found
between 3 and 6 days after the onset of symptoms, most highly
increased liver enzyme levels were found later during the course
of disease.
Preexisting dengue antibodies were the most significant risk
factor for both spontaneous bleeding and other severe dengue
manifestations. This is supported by a previously published
observation, in which travelers of non-European origin had a
4-fold higher risk of developing DHF [20]. However, not all
severe cases can be explained by this: 50% of our patients with
bleeding or other severe manifestations demonstrated a primary
immune response, which is underlined by the fact that 30% of
them visited dengue-endemic areas for the first time. None-
theless, these findings emphasize the need for more-stringent
protection against mosquito bites for travelers with previous
dengue infections or of non-European origin, as well as a careful
evaluation and follow-up of such patients who return home
sick after visiting a country in which dengue is endemic.
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